Comparative Pharmacology
Head-to-head clinical analysis: POLYCILLIN versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYCILLIN versus VERSAPEN.
POLYCILLIN vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polycillin (ampicillin) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
250-500 mg orally every 6 hours or 500 mg intravenously every 4-6 hours for moderate to severe infections.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is 0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in anuria.
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Renal excretion of unchanged drug accounts for 60-80% via glomerular filtration and tubular secretion; 20-40% is hepatically metabolized and eliminated in bile/feces.
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic